WithdrawnEarly Phase 1

Allogeneic Cord Blood for Neurological Diseases in Adults

Stopped: Due to regulatory reasons

0Started 2025-07-01

Plain-language summary

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood therapy for adult patients with neurological diseases.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ischemic or hemorrhagic stroke (onset \< 24 months), or * Spinal cord injury (onset \< 24 months) Exclusion Criteria: * Raised intracranial pressure * Malignant cancer * Renal failure * Severe pulmonary dysfunction

What they're measuring

Changes in modified Rankin Scale (mRS)

Timeframe: 1 month - 3 months - 6 months - 12 months

Trial details

NCT IDNCT05515419

SponsorThe Medical Pavilion Bahamas

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-30

View on ClinicalTrials.gov More Neurological Diseases trials